Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 3/2011

Open Access 01-06-2011

Genome-Wide Association Studies in Atherosclerosis

Authors: S. Sivapalaratnam, M. M. Motazacker, S. Maiwald, G. K. Hovingh, J. J. P. Kastelein, M. Levi, M. D. Trip, G. M. Dallinga-Thie

Published in: Current Atherosclerosis Reports | Issue 3/2011

Login to get access

Abstract

Cardiovascular disease remains the major cause of worldwide morbidity and mortality. Its pathophysiology is complex and multifactorial. Because the phenotype of cardiovascular disease often shows a marked heritable pattern, it is likely that genetic factors play an important role. In recent years, large genome-wide association studies have been conducted to decipher the molecular mechanisms underlying this heritable and prevalent phenotype. The emphasis of this review is on the recently identified 17 susceptibility loci for coronary artery disease. Implications of their discovery for biology and clinical medicine are discussed. A description of the landscape of human genetics in the near future in the context of next-generation sequence technologies is provided at the conclusion of this review.
Literature
1.
Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa heart study. N Engl J Med. 1998;338:1650–6.PubMedCrossRef
2.
Marenberg ME, Risch N, Berkman LF, et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041–6.PubMedCrossRef
3.
Sivapalaratnam S, Boekholdt SM, Trip MD et al. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart 2010
4.
Aouizerat BE, Allayee H, Cantor RM, et al. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am J Hum Genet. 1999;65:397–412.PubMedCrossRef
5.
Wang L, Fan C, Topol SE, et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578–81.PubMedCrossRef
6.
Wang Q, Rao S, Topol EJ. Miscues on the "lack of MEF2A mutations" in coronary artery disease. J Clin Invest. 2005;115:1399–400.PubMedCrossRef
7.
Guella I, Rimoldi V, Asselta R, et al. Association and functional analyses of MEF2A as a susceptibility gene for premature myocardial infarction and coronary artery disease. Circ Cardiovasc Genet. 2009;2:165–72.PubMedCrossRef
8.
Lieb W, Mayer B, Konig IR, et al. Lack of association between the MEF2A gene and myocardial infarction. Circulation. 2008;117:185–91.PubMedCrossRef
9.
Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science. 2007;315:1278–82.PubMedCrossRef
10.
Sarzani R, Salvi F, Bordicchia M et al. Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant. Nutr Metab Cardiovasc Dis. 2009
11.
Tomaszewski M, Charchar FJ, Barnes T, et al. A common variant in low-density lipoprotein receptor-related protein 6 gene (LRP6) is associated with LDL-cholesterol. Arterioscler Thromb Vasc Biol. 2009;29:1316–21.PubMedCrossRef
12.
Crosslin DR, Shah SH, Nelson SC, et al. Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. Hum Genet. 2009;125:217–29.PubMedCrossRef
13.
Shen GQ, Li L, Girelli D, et al. An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. Am J Hum Genet. 2007;81:780–91.PubMedCrossRef
14.
Lanktree MB, Dichgans M, Hegele RA. Advances in genomic analysis of stroke: what have we learned and where are we headed? Stroke. 2010;41:825–32.PubMedCrossRef
15.
Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76.PubMedCrossRef
16.
Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296:2225–9.PubMedCrossRef
17.
Keating BJ, Tischfield S, Murray SS, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE. 2008;3:e3583.PubMedCrossRef
18.
•• Musunuru K and Kathiresan S. Genetics of coronary artery disease. Annu. Rev. Genomics Hum. Genet. 2010, 11: 91–108. This is an excellent review on the current status of genetic studies with CVD as the endpoint.PubMedCrossRef
19.
Schunkert H, Erdmann J, Samani NJ. Genetics of myocardial infarction: a progress report. Eur Heart J. 2010;31:918–25.PubMedCrossRef
20.
•• Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466: 707–13. This article uses a combination of GWA study meta-analyses and gene expression data to proof the importance of novel candidate genes for lipid metabolism. A novel gene, GALNT2, has been described in more detial in a novel mouse model.PubMedCrossRef
21.
McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488–91.PubMedCrossRef
22.
Samani NJ, Schunkert H. Chromosome 9p21 and cardiovascular disease: the story unfolds. Circ Cardiovasc Genet. 2008;1:81–4.PubMedCrossRef
23.
Kathiresan S, Voight BF, Purcell S et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009
24.
Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443–53.PubMedCrossRef
25.
Samani NJ, Deloukas P, Erdmann J, et al. Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol. 2009;29:774–80.PubMedCrossRef
26.
Musunuru K, Post WS, Herzog W, et al. Association of single nucleotide polymorphisms on chromosome 9p21.3 with platelet reactivity: a potential mechanism for increased vascular disease. Circ Cardiovasc Genet. 2010;3:445–53.PubMedCrossRef
27.
Bjorck HM, Lanne T, Alehagen U, et al. Association of genetic variation on chromosome 9p21.3 and arterial stiffness. J Intern Med. 2009;265:373–81.PubMedCrossRef
28.
Cunnington MS, Santibanez KM, Mayosi BM, et al. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet. 2010;6:e1000899.PubMedCrossRef
29.
Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217–24.PubMedCrossRef
30.
Folkersen L, Kyriakou T, Goel A, et al. Relationship between CAD risk genotype in the chromosome 9p21 locus and gene expression. Identification of eight new ANRIL splice variants. PLoS ONE. 2009;4:e7677.PubMedCrossRef
31.
32.
Visel A, Zhu Y, May D, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010;464:409–12.PubMedCrossRef
33.
Jarinova O, Stewart AF, Roberts R, et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol. 2009;29:1671–7.PubMedCrossRef
34.
•• Musunuru K, Strong A, Frank-Kamenetsky M et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010, 466: 714–19. This article describes the approach to identify a GWA signal and translate it into a functional mechanism using mouse models, in vitro studies, and also large cohorts to identify the QTL signal.PubMedCrossRef
35.
Kjolby M, Andersen OM, Breiderhoff T, et al. Sort1, encoded by the cardiovascular risk locus 1p13.3, is a regulator of hepatic lipoprotein export. Cell Metab. 2010;12:213–23.PubMedCrossRef
36.
Goldstein JL, Sobhani MK, Faust JR, Brown MS. Heterozygous familial hypercholesterolemia: failure of normal allele to compensate for mutant allele at a regulated genetic locus. Cell. 1976;9:195–203.PubMedCrossRef
37.
Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006;78:410–22.PubMedCrossRef
38.
Huijgen R, Vissers MN, Defesche JC, et al. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther. 2008;6:567–81.PubMedCrossRef
39.
van Aalst-Cohen ES, Jansen AC, Tanck MW, et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J. 2006;27:2240–6.PubMedCrossRef
40.
Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476–88.PubMed
41.
Tregouet DA, Konig IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009;41:283–5.PubMedCrossRef
42.
Kamstrup PR. Lipoprotein(a) and ischemic heart disease–a causal association? A review. Atherosclerosis. 2010;211:15–23.PubMedCrossRef
43.
Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol. 1999;10:133–41.PubMedCrossRef
44.
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–9.PubMedCrossRef
45.
Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28.PubMedCrossRef
46.
Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008;28:1897–908.PubMedCrossRef
47.
Gleissner CA, von Hundelshausen P, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol. 2008;28:1920–7.PubMedCrossRef
48.
Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 2008;102:209–17.PubMedCrossRef
49.
van Gils JM, da Costa Martins PA, Mol A, et al. Transendothelial migration drives dissociation of plateletmonocyte complexes. Thromb Haemost. 2008;100:271–9.PubMed
50.
Erdmann J, Grosshennig A, Braund PS, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet. 2009;41:280–2.PubMedCrossRef
51.
Nunez RN, Lee IN, Banno A, et al. Characterization of R-ras3/m-ras null mice reveals a potential role in trophic factor signaling. Mol Cell Biol. 2006;26:7145–54.CrossRef
52.
Folkersen L, van’t Hooft F, Chernogubova E, et al. Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease. Circ Cardiovasc Genet. 2010;3:365–73.PubMedCrossRef
53.
Allen PB, Greenfield AT, Svenningsson P, et al. Phactrs 1–4: a family of protein phosphatase 1 and actin regulatory proteins. Proc Natl Acad Sci USA. 2004;101:7187–92.PubMedCrossRef
54.
Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345:971–80.PubMedCrossRef
55.
Armendariz AD, Krauss RM. Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. Curr Opin Lipidol. 2009;20:106–11.PubMedCrossRef
56.
Prudente S, Morini E, Trischitta V. Insulin signaling regulating genes: effect on T2DM and cardiovascular risk. Nat Rev Endocrinol. 2009;5:682–93.PubMedCrossRef
57.
Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet. 2009;41:342–7.PubMedCrossRef
58.
Tsai CT, Lai LP, Hwang JJ, et al. Molecular genetics of atrial fibrillation. J Am Coll Cardiol. 2008;52:241–50.PubMedCrossRef
59.
Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150:65–72.PubMed
60.
Talmud PJ, Cooper JA, Palmen J, et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem. 2008;54:467–74.PubMedCrossRef
61.
Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747–53.PubMedCrossRef
62.
Vissers LE, de Ligt J, Gilissen C, et al. A de novo paradigm for mental retardation. Nat Genet. 2010;42:1109–12.PubMedCrossRef
Metadata
Title
Genome-Wide Association Studies in Atherosclerosis
Authors
S. Sivapalaratnam
M. M. Motazacker
S. Maiwald
G. K. Hovingh
J. J. P. Kastelein
M. Levi
M. D. Trip
G. M. Dallinga-Thie
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 3/2011
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0173-4

Other articles of this Issue 3/2011

Current Atherosclerosis Reports 3/2011 Go to the issue

ReviewPaper

Genetics of Redox Systems and Their Relationship with Cardiovascular Disease

ReviewPaper

MicroRNAs in Cardiometabolic Disease

ReviewPaper

Utility of Atherosclerosis Imaging in the Evaluation of High-Density Lipoprotein–Raising Therapies

Clinical Trial Report

Genome-Wide Association Studies Complemented with Mechanistic Biological Studies Identify Sortilin 1 as a Novel Regulator of Cholesterol Trafficking

ReviewPaper

Role of Hepatic Lipase and Endothelial Lipase in High-Density Lipoprotein—Mediated Reverse Cholesterol Transport

ReviewPaper

Genetic Mechanisms Mediating Atherosclerosis Susceptibility at the Chromosome 9p21 Locus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits